Project Grant R01AI197964
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $358K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94110, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $842,888 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify immunological and transcriptional factors associated with treatment outcomes in drug-susceptible tuberculosis. The recipient will conduct transcriptional profiling of whole blood to define pathways and genetic regulatory networks associated with shorter time...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $1.134 million on September 18, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the causality of post-TB lung disease in a population-based prospective cohort study in rural Uganda. The research evaluates pre-TB and post-TB lung function and respiratory symptoms to distinguish whether post-TB lung disease sequelae stem from TB itself or from underlying...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $798,107 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish a tissue-based understanding of tuberculosis-associated lung fibrosis and post-TB lung disease pathology. The project creates a baseline understanding of molecules and cells driving fibrogenesis during TB infection, with the goal of identifying adjunctive therapies to modulate tissue...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $463,601 to The Regents of the University of California, San Francisco on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research investigating how cytomegalovirus (CMV) infection compromises immune control of Mycobacterium tuberculosis (MTB), the pathogen causing tuberculosis. The research employs a murine co-infection...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Washington $1,343,164 on July 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into asymptomatic tuberculosis transmission, infectiousness, and immunology conducted in Nairobi, Kenya. The research investigates the infectiousness spectrum of asymptomatic TB, identifies risk factors for increased...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $4.760584 million on September 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II). UCSF will solicit, review, and prioritize novel tuberculosis diagnostics across different phases of development and use cases for evaluation. The work...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $427,623 to The Washington University on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research dissecting how HIV-induced immunometabolic perturbation impairs tuberculosis control in people living with HIV despite effective antiretroviral therapy and viral suppression. The research...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Santa Cruz $259,415 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to determine the functional role of long non-coding RNAs (lncRNAs) in tuberculosis infection within macrophages. The research investigates post-transcriptional regulatory mechanisms that control innate immune response to Mycobacterium tuberculosis. The work follows preliminary screening of...
- The National Institute of Allergy and Infectious Diseases awarded Weill Medical College of Cornell University $2,217,926 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the determinants of tuberculosis control, relapse, and reinfection caused by Mycobacterium tuberculosis. The award funds a tri-institutional program project focused on understanding persistent states of TB infection, specifically latent TB infection (LTBI) and...
- The National Institute of Allergy and Infectious Diseases awarded $1.59 million to the University of Colorado-Denver under Project Grant R01AI187511 on September 17, 2025, to support research integrating genomic architecture and tuberculosis immunity in Africa under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research generates population-level genetic data (HLA, KIR, and SNP array) on 5,000 case/control samples from multi-ancestry individuals in South Africa's...